Andrew Hertler, MD, FACP

Which components of the recently announced Cancer Moonshot should get high priority for the initiative to succeed? Our chief medical officer, Dr. Andrew Hertler, outlines three key questions to track.

The FDA's Aduhelm approval was highly controversial, but not as surprising for those who follow the oncology drug pipeline.

Our chief medical officer highlights noteworthy research and results from clinical oncology's premier event.

Our CMO Dr. Andrew Hertler explains how real world evidence may usher in the next generation of clinical oncology pathways.

The pandemic has forced difficult trade-offs between cancer treatment and infection prevention. We also need to be willing to make hard decisions around value, our CMO writes.

Our CMO Dr. Andrew Hertler offers insights for minimizing patients' risk of COVID-19 when their cancer therapies cannot be delayed.

Prior authorization is a major source of frustration for providers and patients. Our CMO Dr. Andrew Hertler explains how a value-based approach can change that.

Our CMO Dr. Andrew Hertler outlines value-based payment strategies and tools to help oncologists improve care across the patient journey.

Dr. Hertler, CMO at New Century Health, shares his thoughts and perspectives on the future of CAR T-cell therapy and the recent CMS announcements.

Dr. Hertler, Chief Medical Officer at New Century Health, and others describe the potential of big data and predictive analytics to improve clinical risk stratification for cancer patients.

Dr. Andrew Hertler, Chief Medical Officer at New Century Health, demonstrates how clinical pathways improve patient outcomes while decreasing waste and cost.